Point72 Asset Management
PGNX

Point72 Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Point72 Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,785,100
Closed -$14.1M – 1394
2019
Q3 		$14.1M Sell
2,785,100
-3,073,649
-52% -$15.3M 0.09% 283
2019
Q2 		$36.1M Buy
5,858,749
+58,749
+1% +$283K 0.22% 142
2019
Q1 		$26.9M Buy
5,800,000
+1,025,000
+21% +$4.64M 0.15% 194
2018
Q4 		$20.1M Buy
+4,775,000
New +$24.3M 0.12% 256

Other funds holding PGNX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $403M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return